Table 3.
Current clinical trials targeting the PI3K/AKT/mTOR/NFκB pathway in OvCa.
| Drug | Target | Clinical Trial | NCT Trial |
|---|---|---|---|
| CUDC-907 | PI3K/HDAC | Phase 1 | NCT02307240 |
| Copanlisib | PI3K | Phase 1b | NCT03586661 |
| BKM120/BYL719 | PI3K | Phase 1 | NCT01623349 |
| MK2206 | AKT | Phase 2 | NCT01283035 |
| BKM120 + MEK162 | PI3K | Phase 1 | NCT01363232 |
| AZD5363 | AKT | Phase 1 | NCT01226316 |
| GSK2141795 | AKT | Phase 1 | NCT01266954 |
| Triciribine (PTX-200) | AKT | Phase 1 | NCT01690468 |
| Miransertib(ARQ 092) | AKT | Phase 1b | NCT02476955 |
| Perifosine | PI3K/ AKT | Phase 1 | NCT00431054 |
| Sapanisertib | mTOR | Phase 2 | NCT02465060 |
| Everolimus | mTOR | Phase 2 | NCT01149434 |
| Nanoparticle albumin-bound rapamycin | mTOR | Phase 1 | NCT02646319 |
| Sirolimus | mTOR | Phase 1 | NCT02833506 |
| TAK228 | PI3K/ AKT/mTOR | Phase 2 | NCT03648489 |
| MLN0128 | TORC 1/2 | Phase 1 | NCT02142803 |
| Temsirolimus | mTOR | Phase 2 | NCT02093598 |
| AZD2014 | mTOR | Phase 1b | NCT02208375 |
| IMX-110 | Stat3/NF-kB/poly-tyrosine kinase | Phase 1/2a | NCT03382340 |